Intracellular metabolic alterations have been observed upon treatment with EGFR TKIs [15,16,17] and provides a rationale for investigating if targeting tumor metabolism adjuvant or concurrently with EGFR TKIs would improve therapeutic efficacy. The gene discussed is EGFR; the disease is neoplasm.